drugset / Trial / NCT00694798

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder

NCT00694798 ↗

Phase 1 Completed 22 enrolled Cadila Pharnmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the response rate of this treatment (Mw) in patients with BCG refractory superficial transitional cell carcinoma. Other objectives include detecting the effect of Mw on Time to Tumor progression and evaluating safety.

Timeline

Start
2008-10
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycobacterium w Vaccine — —